skip to Main Content

InflaRx raises financing to develop a new therapeutic approach against sepsis

  • 2008

InflaRx GmbH, announced today the clos­ing of its seed financ­ing led by Affen­tranger Asso­ciates along­side with bm|t beteili­gungs­man­age­ment thürin­gen gmbh. InflaRx’s mis­sion is to develop new ther­a­peu­tic approaches to pre­vent and treat sep­sis. Cre­ated by Prof. Niels Riede­mann and Prof Ren­feng Guo, two world­wide rec­og­nized researchers in the field of inflam­ma­tion and sep­sis, InflaRx has already brought its lead­ing devel­op­ment pro­gram tar­get­ing acti­va­tion prod­ucts of the com­ple­ment sys­tem in an advanced pre-clin­i­cal stage.

Aware of many tar­gets which have failed in the past, we are devel­op­ing a new break­through approach to address the sep­sis indi­ca­tion by com­bin­ing our state of the art R&D pro­gram with the world­wide rec­og­nized clin­i­cal sep­sis research cen­ter in Jena” says Prof. Niels Riede­mann CEO of InflaRx. “The high poten­tial of InflaRx of address­ing a crit­i­cal unmet med­ical need with a new very promis­ing tar­get and a clear clin­i­cal strat­egy has been rec­og­nized by the seed investor group” adds Nico­las Fulpius, Chair­man of the board of InflaRx and Part­ner at Affen­tranger Asso­ciates. “The com­pe­tence of InflaRx will cre­ate strong syn­er­gies for Jena as fast grow­ing cen­ter of sep­sis exper­tise” under­lines. Dr. Guido Bohnenkamp, Man­ag­ing Direc­tor of bm|t.

As of today, sep­sis – also called blood poi­son­ing in the pub­lic press – is the most fre­quent cause of death in non-car­di­o­log­i­cal inten­sive care units world­wide. With over 1.5 mil­lion cases in Europe and North Amer­ica alone, and with mor­tal­ity rates up to 50%, sep­sis remains one of the largest and least pub­licly rec­og­nized unmet med­ical needs.

Based in Jena (Ger­many), a world­wide rec­og­nized sep­sis research hub , InflaRx is devel­op­ing its inno­v­a­tive ther­a­peu­tic pro­grams in coöper­a­tion with the Uni­ver­sity Hos­pi­tal of the Friedrich Schiller Uni­ver­sity in Jena, the Uni­ver­sity of Michi­gan in USA and Bei­jing Mab­works Biotech Co., LTD in China. The Sci­en­tific Advi­sory Board of InflaRx is com­posed by two world lead­ers in the field of basic sep­sis research with Prof P. Ward at the Uni­ver­sity of Michi­gan and clin­i­cal sep­sis research with Prof. K. Rein­hart at the Friedrich-Schiller-Uni­ver­sity in Jena.

About Affentranger Associates SA

Incor­po­rated in 2002, Affen­tranger Asso­ciates is a Switzer­land based busi­ness plat­form focused on the theme of value cre­ation and active man­age­ment. As prin­ci­pal investor, the com­pany has the ambi­tion to achieve sus­tain­able long-term returns by invest­ing with a com­bi­na­tion of man­age­ment and cap­i­tal in high-growth poten­tial com­pa­nies. Affen­tranger Asso­ciates has offices in Geneva and Zurich.

For more infor­ma­tion please visit www.aasa.com

Press contact

Affen­tranger Asso­ciates SA
Nico­las Fulpius

100 rue du Rhône
CH-1204 Geneva
+41 228 180–180
 www.aasa.com

InflaRx GmbH
Prof. Niels Riedemann

Winz­er­laer Straße 2
D‑07745 Jena
+49 (0) 3641 508–180
Back To Top
×Close search
Search